CXCL16 and prostate carcinoma: One potential candidate is AKT/mammalian target of rapamycin (mTOR) signaling pathway because CXCL16 has been reported to promotes prostate cancer progression by activating the AKT/mTOR signaling pathway [31], which is abolished by rapamycin, a mTOR inhibitor and an anti-aging and anti-cancer drug [32, 33].